API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Cerecor’s pipeline now includes six clinical-stage assets, accelerating the company’s transformation into a research organization focused on developing new medicines for unmet needs in rare diseases.
Lead Product(s): Rislenemdaz
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cerecor
Deal Size: $22.1? million Upfront Cash: Undisclosed
Deal Type: Acquisition February 03, 2020